Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RED4MS Trial
NCT06430671Phase 1Completed
- Sponsor
- Cellerys AG
- Start
- Jun 2024
- Primary completion
- Dec 2025
- Modality
- Cell Therapies
- Countries
- 4
01
Overview
Phase 1, open-label trial of CLS12311 in relapsing-remitting multiple sclerosis (RRMS) (3 arms), sponsored by Cellerys AG. Primary endpoint: Treatment-Emergent Adverse Events at 48 weeks. Started Jun 2024; status: completed.
02
Drugs
CLS12311
03
Conditions
relapsing-remitting multiple sclerosis (RRMS)
Beyond the preview
Go deeper on NCT06430671.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06430671.